Flex Steel
Total Consideration
$627.5M
Pro-Forma Combined Entity
Revenue
$1.15B
Net Income
+$181.0M
Cactus, Inc. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
52-Week Range
Trailing Returns
ROIC vs WACC
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
—
Book Value Per Share
—
Free Cash Flow Per Share
—
Cash Per Share
—
Revenue Per Share
—
OCF Per Share
—
Return on Equity
14.5%
Return on Assets
9.2%
Return on Invested Capital
16.9%
Debt to Equity
0.00
Current Ratio
5.81
Quick Ratio
5.81
Asset Turnover
0.60
Days Sales Outstanding
55.64
Days Payables Outstanding
38.42
SBC / Revenue
2.3%
Working Capital
$791M
Net Current Asset Value
$516M
Invested Capital
$1.23B
OCF / Net Income
1.56
FCF / Net Income
1.56
Accruals Ratio (Sloan)
-4.9%
Net Debt
$-124M
Net Debt / EBITDA
-0.39
Interest Coverage
360.43
Cash Coverage
371.82
Dividend Coverage
6.90
Tangible Common Equity
$875M
TCE / Total Assets
46.8%
Goodwill / Total Assets
10.8%
NOPAT
$194M
Cash ROIC
22.5%
WC / Revenue
73.3%
Reinvestment Rate
-25.5%
Total Payout Ratio
26.1%
Asset Growth vs Revenue Growth
12.1%
Revenue 5Y CAGR
25.4%
EPS 5Y CAGR
37.0%
FCF 5Y CAGR
12.5%
EBITDA 5Y CAGR
23.2%
Book Value 5Y CAGR
17.4%
Stock Price (FY-end)
$46
Market Cap
—
P/E Ratio
—
P/S Ratio
—
P/B Ratio
—
P/TB Ratio
—
P/OCF Ratio
—
P/FCF Ratio
—
Enterprise Value
—
EV / EBITDA
—
EV / Sales
—
EV / FCF
—
FCF Yield
—
Dividend Yield
—
Shareholder Yield
—
Buyback Yield
—
Dividend Per Share
—
Operating Leverage
3.01
Graham Number
—
Beta (5Y)
1.16
Cost of Equity
10.3%
Cost of Debt (after tax)
—
52W High
$63
52W Low
$33
Trailing Return 1Y
-19.3%
Trailing Return 5Y
81.9%
F-Score (Piotroski)
4.00
Z-Score (Altman)
—
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
Cactus, Inc. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | — | — | — | — | — | 21.00% |
| State & Local Income Taxes | — | — | — | — | — | 1.80% |
| Foreign Rate Differential | — | — | — | — | — | 0.90% |
| Other Adjustments | — | — | — | — | — | 0.80% |
| Valuation Allowance Change | — | — | — | — | — | 0.90% |
| Effective Tax Rate | 15.60% | 10.20% | 17.80% | 18.10% | 22.20% | 22.60% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $11.0M | $7.7M | $31.4M | $47.5M | $66.5M | $59.0M |
| Income Taxes Paid (Cash) | — | — | — | — | — | $48.1M |
Cactus, Inc. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.